Cover Image
Market Research Report

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

Published by Datamonitor Healthcare Product code 914886
Published Content info 117 Pages
Delivery time: 1-2 business days
Price
Back to Top
2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
Published: October 18, 2019 Content info: 117 Pages
Description

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for non-small lung cancer and Kisqali for breast cancer.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

Table of Contents
Product Code: #BMT

Table of Contents

Summary

About the Author

Disclaimer

Drug Abstracts

Biliary Tract Cancer

  • Pemigatinib for Biliary Tract Cancer (INCY, Phase III)
  • Tibsovo for Biliary Tract Cancer (AGIO, Phase III)

Bladder Cancer

  • Enfortumab Vedotin for Bladder Cancer (Astellas, BLA)
  • Sacituzumab Govitecan for Bladder Cancer (IMMU, Phase II)
  • Tecentriq for Bladder Cancer (RHHBY, Approved)

Breast Cancer

  • G1T48 for Breast Cancer (G1 Therapeutics, Phase I)
  • Keytruda for Breast Cancer (MRK, Phase III)
  • Keytruda for Breast Cancer (MRK, Phase III)
  • Kisquali for Breast Cancer (NVS, Approved)
  • Trilaciclib for Breast Cancer (G1 Therapeutics, Phase II)
  • Verzenio for Breast Cancer (LLY, Approved)

Colorectal Cancer

  • AMG 510 for Colorectal Cancer (CRC) (AMGN, Phase I)
  • Braftovi for Colorectal Cancer (CRC) (PFE, Phase III)
  • Tucatinib for Colorectal Cancer (CRC) (PFE, Phase III)

Esophageal Cancer

  • Opdivo for Esophageal Cancer (BMY, Phase III)

Gastric Cancer

  • Margetuximab for Gastric Cancer (MGNX, Phase II)

Head and Neck Cancer

  • Debio 1143 for Head and Neck Cancer (Debiopharm, Phase II)
  • Monalizumab for Head and Neck Cancer (AZN, Phase II)
  • Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
  • Opdivo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (BMY, Approved)
  • Tecentriq for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (RHHBY, Phase III)
  • Non-Small Cell Lung Cancer (NSCLC)
  • AMG 510 for Non-Small Cell Lung Cancer (NSCLC) (AMGN, Phase I)
  • Opdivo for Non-Small Cell Lung Cancer (NSCLC) (BMY, Approved)
  • Tagrisso for Non-Small Cell Lung Cancer (NSCLC) (AZN, Approved)
  • Tecentriq for Non-Small Cell Lung Cancer (NSCLC) (RHHBY, Approved)

Ovarian Cancer

  • AVB-500 for Ovarian Cancer (ARAV, Phase II)
  • Lynparza for Ovarian Cancer (AZN, Approved)
  • M6620 for Ovarian Cancer (MKGAY, Phase II)
  • Mirvetuximab Soravtansine for Ovarian Cancer (IMGN, Phase III)
  • Veliparib for Ovarian Cancer (ABBV, Phase III)
  • Zejula for Ovarian Cancer (GSK, Approved)

Prostate Cancer

  • Erleada for Prostate Cancer (JNJ, Approved)
  • Lynparza for Prostate Cancer (AZN, Phase III)
  • Rubraca for Prostate Cancer (CLVS, Phase III)
  • SM-88 for Prostate Cancer (TYME, Phase II)
  • Zejula for Prostate Cancer (GSK, Phase III)
  • Renal Cell Cancer (RCC)
  • Mavorixafor for Renal Cell Cancer (RCC) (XFOR, Phase II)
  • MK-6482 for Renal Cell Cancer (RCC) (MRK, Phase II)
  • Tivopath (Oncology) for Renal Cell Cancer (RCC) (AVEO, Phase III)

Solid Tumors

  • ALRN-6924 for Solid Tumors (ALRN, Phase II)

Thyroid Cancer

  • Selpercatinib for Thyroid Cancer (LLY, Phase II)

List of Biomedtracker ESMO Events

Back to Top